MDMA Therapy's Second Shot at FDA Approval Skips the One Thing That Sank It Last Time

As of this month, no classic psychedelic — not psilocybin, not MDMA, not LSD, not DMT, not ibogaine — has FDA approval for anything, for anyone, at any dose. That fact hasn’t moved in years, despite headline after headline about breakthrough trial data. What’s changed this year isn’t the approval count. It’s how many separate tracks are now running at once toward the same door.

Three things are happening simultaneously this year that were not happening two years ago: a rejected drug is trying again without redoing the trial that got it rejected, a second drug is moving through review on a fast lane built for it, and the FDA is about to hold a public hearing on the entire category at once. None of the three guarantees an approval. Together, they’re the clearest sign yet that the agency has stopped treating psychedelics as a single, undifferentiated no.

The drug that’s trying again without the do-over

In August 2024, the FDA rejected MDMA-assisted therapy for PTSD, developed by Lykos Therapeutics, largely over concerns about blinding — in a psychedelic trial, patients and therapists alike can usually tell within the first session whether they got the real drug or the placebo, which makes it hard to separate the treatment’s actual effect from the power of knowing you got it. That’s not a minor statistical quibble; it’s a structural problem with how you prove any psychedelic works in a randomized trial, and it’s one the whole field has had to reckon with since. This month, the same drug is back in front of the FDA under a new name — Resilient Pharmaceuticals, the company Lykos became — without a new phase 3 efficacy trial. The resubmission leans instead on a third-party audit of the original data, a new phase 1 cardiac-safety study, and long-term follow-up data gathered through the VA, which has been running its own MDMA-assisted therapy programs for veterans with PTSD outside the commercial approval pathway.

Translate that plainly: the company isn’t claiming it found new proof the drug works. It’s arguing the original proof was sound all along, and that the 2024 rejection was more about trial design than about whether patients actually got better. Whether the FDA agrees is the whole ballgame, and it’s genuinely an open question — the blinding problem that sank the first application hasn’t disappeared just because a different document explains around it.

That blinding problem, notably, got an actual regulatory answer this summer. The FDA finalized guidance in July for how psychedelic trials should handle unblinding going forward — a rulebook that didn’t exist when Lykos ran its original trials. That guidance won’t retroactively fix the MDMA resubmission’s data, but it tells you the agency is building permanent infrastructure for this drug class rather than handling each application as a one-off. That’s the kind of signal that matters more, long-term, than any single yes or no.

The one moving fastest: psilocybin

While MDMA fights its rejection, psilocybin has been moving on a track built for speed. Compass Pathways’ COMP360 — a synthetic, standardized dose of psilocybin paired with structured psychotherapy for treatment-resistant depression — is in rolling New Drug Application review, with the final data module expected in the fourth quarter of 2026. Rolling review means the FDA is reading sections of the application as they’re finished instead of waiting for the whole thing at once — a mechanism usually reserved for treatments the agency has already flagged as addressing a serious, unmet need. In April, the FDA moved to fast-track review of psilocybin and methylone specifically for mental health conditions through its priority voucher program, the same mechanism that’s sped up approvals in oncology and rare disease.

Here’s the plain-language version of why psilocybin works, for anyone who’s heard “serotonin receptor” thrown around without the follow-up sentence: psilocybin binds strongly to a specific serotonin receptor (5-HT2A) that appears to loosen rigid, well-worn patterns of thought — the same mental grooves that keep someone locked in a depressive spiral, replaying the same defeated story about themselves. Paired with structured psychotherapy sessions before and after dosing, the idea isn’t that the drug alone fixes anything; it’s that the drug opens a window during which new patterns of thinking are more available to be practiced and reinforced, with a trained therapist in the room to help make that practice stick. That’s a psychological mechanism, not just a pharmacological one — which is exactly why every serious protocol pairs the dose with therapy hours, not a prescription bottle you take home alone.

The hearing that decides less than it sounds like

On September 14, the FDA will hold a hybrid public hearing specifically on the future therapeutic use of psychedelic drugs in supervised treatment settings, gathering public comment on everything from how these treatments should be dosed and supervised to how insurers might eventually cover them. It’s worth naming the gate here plainly, because it’s easy to overread: a public hearing is not a vote and doesn’t approve or reject anything. What it does is put the entire category — not just one drug’s application — in front of the agency’s decision-makers at once, at the same moment two separate applications are moving through review. Read together, the hearing, the finalized trial guidance, and two live applications look less like coincidence and more like an agency deliberately building the regulatory shelf this class of drugs needs before it lets one onto it.

It’s worth naming the gate here plainly, because it’s easy to overread: a public hearing is not a vote and doesn’t approve or reject anything.

The history this is finally answering to

This isn’t the first time American medicine took psychedelics seriously. In the 1950s and 60s, LSD and psilocybin were the subject of more than a thousand published studies and were used experimentally to treat alcoholism, anxiety in terminal patients, and treatment-resistant depression — some of that early research methodologically shaky by today’s standards, some of it genuinely promising. Then, in 1970, the Controlled Substances Act placed the classic psychedelics in Schedule I — the category reserved for drugs with, on paper, no accepted medical use and high abuse potential — and federally funded research on them effectively stopped for roughly three decades. It wasn’t new safety data that ended the research era; it was a political and cultural backlash to recreational use in the counterculture that swept the therapeutic evidence out with it. The current wave of trials is, in a very real sense, medicine re-litigating a case it was never allowed to finish arguing the first time, using the rigor — blinding protocols, phase 3 trials, FDA guidance documents — that the field never got to build under Schedule I.

If you’re someone who’s used psychedelics outside a clinical setting, this isn’t a signal to try to replicate a therapy protocol on your own — the structured therapy hours are the part of the model doing real safety and integration work, not an optional add-on, and self-directed use carries risks a supervised trial is specifically designed to manage. What this year’s parallel tracks actually mean, for a treatment provider watching this science and medicine beat from outside the trials, is that “psychedelic-assisted therapy” is stopping being a single speculative category and starting to split into drugs with real regulatory timelines attached — worth knowing which one, if any, is closest to your state’s scope-of-practice rules before a patient asks. Nothing here is approved yet. But for the first time since 1970, the shelf is being built in public, one hearing and one rolling review at a time.